Israel’s BrainStorm Receives $2.1 Million Grant to Support Development of Stem-Cell Therapy NurOwn to Treat ALS
The Israel Innovation Authority (IIA) has awarded BrainStorm Cell Therapeutics a $2.1 million grant to support the development of NurOwn, an innovative mesenchymal stem cell-based platform to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS).